Updated:Bribery and tax law violation. China's accused GlaxoSmithKline of both - in the biggest case of graft involving a foreign firm in China, in three years. The charges include offering bribes to Chinese government officials, medical associations, hospitals and doctors - to boost sales and prices. China also says GSK violated the tax law by faking receipts. Its security minister says it's received confessions from the executives. But it's not said how many - or who they are.